ClinicalTrials.gg
CompletedNCT01221597Updated Oct 5, 2017Results posted

Study of AA4500 in the Treatment of Peyronie's Disease

A Phase 3 interventional study of AA4500 and Placebo in Peyronie's Disease, sponsored by Endo Pharmaceuticals. Completed at 34 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-05.

Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
418
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing Microbial Collagenase in Penile Induration — none open to participants now, 3 under way, none of them phase 3. Microbial Collagenase · Penile Induration.

Enrollment
Largest of 13
418 · median 40
Started
2010
with 2 others
Phase 3
4 of 13
none open now
Registered
2nd of 13
by date
Lead sponsor
6 of 13
Endo Pharmaceuticals

Among the 13 studies testing Microbial Collagenase in Penile Induration, this one has the largest enrollment, is one of 3 that started in 2010, is one of 4 in phase 3, and was the 2nd registered.

Penile Induration

48 studies on the registry are indexed under Penile Induration; 10 are open to participants now.

Browse Penile Induration studies →

Open to participants now

None of the 13 studies testing Microbial Collagenase in Penile Induration is open now. The open studies under Penile Induration, anywhere →

About Microbial Collagenase

Microbial Collagenase: first FDA approval 1965 (SANTYL), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 8 Penile Induration studies recruiting now, 5 set no upper age limit and 2 stop at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing Microbial Collagenase in Penile Induration as a file.
02

Study summary

This study is a Phase 3, double-blind, randomized, placebo-controlled study of the safety and efficacy of AA4500 0.58 mg in subjects with Peyronie's disease. Approximately 400 (267 AA4500 and 133 placebo) men will be randomized. Subjects will be screened for study eligibility within 21 days before the initial injection of study drug in the first treatment cycle.

Before dosing, subjects will be stratified by degree of penile curvature deformity (ie, 30º to 60º or 61º to 90º) and then randomized into two treatment groups to receive in a 2:1 ratio either AA4500 0.58 mg or placebo.

In this study, qualified subjects may receive up to four treatment cycles; each cycle will be separated by a period of 42 days (± 5 days). During each treatment cycle, subjects will receive two injections of study drug with at least 24 hours but not more than 72 hours between injections. After the final injection of each treatment cycle, the investigator or qualified designee will model the penile plaque in an attempt to stretch or elongate the plaque. If the subject's penile curvature is reduced to \<15 degrees after the first, second, or third cycle of injections or if further treatment is not clinically indicated, subsequent treatment cycles will not be administered.

Following the maximum of four treatment cycles, each subject will be followed for additional safety and efficacy assessments on Days 169 (± 7 days), 232 (± 7 days), 295 (± 7 days), 365 (± 7 days) (nominal weeks 24, 33, 42 and 52). Subjects randomized to placebo may receive open-label AA4500 treatment after completing this study as part of another protocol.

03

Conditions studied

  • Peyronie's Disease

Browse trials for

Keywords

  • Peyronie's Disease
  • penile plaque
  • penile curvature
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be a male and be ≥ 18 years of age
  2. Be in a stable relationship with a female partner/spouse for at least 3 months before screening and be willing to have vaginal intercourse with that partner/spouse
  3. Have symptom(s) of Peyronie's disease for at least 12 months before the first dose of study drug and have evidence of stable disease as determined by the investigator
  4. Have curvature deformity of at least 30° in the dorsal, lateral, or dorsal/lateral plane at screening. It must be possible to delineate the single plane of maximal curvature for evaluation during the study
  5. Be judged to be in good health, based upon the results of a medical history, physical examination, and laboratory profile
  6. Voluntarily sign and date an agreement approved by the Institutional Review Board/Independent Ethics Committee (IRB/IEC). The subject must also sign an authorization form to allow disclosure of his protected health information (PHI). The PHI authorization form and informed consent form may be an integrated form or may be separate forms depending on the institution
  7. Be able to read, complete and understand the various rating instruments in English

Exclusion criteria

Exclusion criteria

  1. Has a penile curvature of less than 30° or greater than 90° at the screening visit
  2. Has any of the following conditions:

    • Chordee in the presence or absence of hypospadias
    • Thrombosis of the dorsal penile artery and/or vein
    • Infiltration by a benign or malignant mass resulting in curvature deformity
    • Infiltration by an infectious agent, such as lymphogranuloma venereum
    • Ventral curvature from any cause
    • Presence of an active sexually transmitted disease
    • Known active or C
    • Known immune deficiency disease or be positive for (HIV)
  3. Has previously undergone surgery for Peyronie's disease
  4. Fails to have an erection which in the opinion of the investigator is sufficient to accurately measure the subject's penile deformity after administration of prostaglandin E1 (PGE1) or trimix
  5. Has a calcified plaque as evident by appropriate radiographic evaluation, penile x-ray or penile ultrasound that would prevent proper injection of study medication. Non-contiguous stippling of calcium is acceptable for inclusion provided the calcium deposit does not interfere with the injection of AA4500 into the plaque
  6. Has an isolated hourglass deformity of the penis
  7. Has the plaque causing curvature of the penis located proximal to the base of the penis, so that the injection of the local anesthetic would interfere with the injection of AA4500 into the plaque
  8. Has previously received alternative medical therapies for Peyronie's disease administered by the intralesional route (including, but not limited to, , verapamil, and the naturally occurring low molecular weight protein, interferon-α2b) within 3 months before the first dose of study drug or plans to use any of these medical therapies at any time during the study
  9. Has received alternative medical therapies for Peyronie's disease administered by the oral (including, but not limited to, vitamin E [> 500 U], potassium aminobenzoate [Potaba], tamoxifen, colchicine, pentoxifylline, over-the-counter erectile dysfunction medications, or steroidal anti-inflammatory drugs) or topical routes (including, but not limited to, verapamil applied as a cream) within 3 months before the first dose of study drug or plans to use any of these medical therapies at any time during the study
  10. Has had extracorporeal shock wave therapy (ESWT) for correction of Peyronie's disease within the 6-month period before screening or plans to have ESWT at any time during the study
  11. Has used any mechanical type device for correction of Peyronie's disease within the 2-week period before screening or plans to use any these devices at any time during the study
  12. Has used a mechanical device to induce a passive erection within the 2-week period before screening or plans to use any of these devices at any time during the study
  13. Has significant erectile dysfunction that has failed to respond to oral treatment with phosphodiesterase type 5 (PDE5) inhibitors
  14. Has a penile Duplex Doppler ultrasound evaluation at screening that shows compromised penile hemodynamics that in the opinion of the investigator is
  15. Has uncontrolled hypertension, as determined by the investigator
  16. Has a known recent history of stroke, bleeding, or other significant medical condition, which in the investigator's opinion would make the subject unsuitable for enrollment in the study
  17. Is unwilling or unable to cooperate with the requirements of the study including completion of all scheduled study visits
  18. Has received an drug or treatment within 30 days before the first dose of study drug
  19. Has a known systemic allergy to collagenase or any other of AA4500
  20. Has a known allergy to any concomitant medication required as per the protocol
  21. Has received anticoagulant medication (except for ≤ 165 mg aspirin daily or ≤ 800 mg of over-the-counter non-steroidal anti-inflammatory drugs [NSAIDS] daily) during the 7 days before each dose of study drug
  22. Has received any collagenase treatments within 30 days of the first dose of study drug
  23. Has, at any time, received AA4500 for the treatment of Peyronie's disease

    -

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
418 participants (actual)

Study arms

  • Experimental
    AA4500

    collagenase clostridium histolyticum

    Biological: AA4500

  • Placebo comparator
    Placebo

    placebo

    Biological: Placebo

Interventions

  • BiologicalAA4500

    2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.

    Also known as: XIAFLEX

  • BiologicalPlacebo

    2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.

06

What researchers measure

Primary outcomes

  1. Percentage Change From Baseline in Penile Curvature

    A negative value in the percentage change from baseline in penile curvature deformity (angle measured in degrees) indicates less curvature.

    Time frame: Baseline and Week 52

  2. Change From Baseline in the Peyronie's Disease Bother Domain of the Peyronie's Disease Questionnaire (PDQ)

    Peyronie's disease bother score range 0 (no issue or not at all bothered) to 4 (extremely bothered) on 4 questions; total score range 0 to 16. A decrease in the change from baseline total score in the Peyronie's disease bother domain of the PDQ is indicated by a negative number.

    Time frame: Baseline and Week 52

Secondary outcomes

  1. A Responder Analysis Based on Subject Overall Global Assessment of Peyronie's Disease

    A responder was defined as a subject who recorded his Peyronie's disease had either improved in a small but important way, moderately improved, or much improved in overall global assessment question.

    Time frame: Week 52

  2. Change From Baseline in the Severity of Peyronie's Disease Physical and Psychological Symptoms

    Peyronie's disease symptoms (physical and psychological) severity score range 0 (none) to 4 (very severe) on 6 questions; total score range 0 to 24. A decrease in the change from baseline total score in the Peyronie's disease symptoms domain of the PDQ is indicated by a negative number.

    Time frame: Baseline and Week 52

  3. Change in the Overall Satisfaction Domain of the International Index of Erectile Function (IIEF)

    Overall satisfaction domain of the IIEF score range 0 to 5 on 2 questions where higher scores indicate improved function or satisfaction; total score range 0 to 10.

    Time frame: Baseline and Week 52

  4. Change From Baseline in Penile Plaque Consistency

    Penile plaque consistency score range 1 (non-palpable) to 5 (hard). A decrease in the change from baseline score in penile plaque consistency is indicated by a negative number.

    Time frame: Baseline and Week 52

  5. Change From Baseline in Penile Length

    A negative value represents a reduction in measurement from baseline.

    Time frame: Baseline and Week 52

  6. Change From Baseline in the Penile Pain Domain of the PDQ in Subjects With Baseline Penile Pain Score ≥4

    Penile pain scale range 0 (no pain) to 10 (extreme pain) on 3 questions; total score range 0 to 30. A decrease in the change from baseline total score in the penile pain domain of the PDQ is indicated by a negative number. Subjects were required to have a penile pain score of 4 or greater at baseline.

    Time frame: Baseline and Week 52

  7. Composite Responder Based on Change in Curvature Deformity and Change in Peyronie's Disease Bother Score

    A responder was defined as a subject who satisfied the following 2 criteria at that visit: a) percent reduction from baseline in curvature deformity was ≥20% and b) reduction from baseline in PDQ Peyronie's disease bother score was ≥1, or had a change from reporting no sexual activity at screening to reporting sexual activity.

    Time frame: Week 52

07

Results

Posted Apr 7, 2015

Participant flow

Participant flow — Overall Study
MilestoneAA4500Placebo
Started277140
Completed241124
Not completed3616
Withdrew: Adverse event41
Withdrew: Withdrawal by subject206
Withdrew: Lost to follow-up65
Withdrew: Protocol violation10
Withdrew: Other34
Withdrew: Death20

Outcome measures

PrimaryPercentage Change From Baseline in Penile Curvature

A negative value in the percentage change from baseline in penile curvature deformity (angle measured in degrees) indicates less curvature.

Time frame:
Baseline and Week 52
Reported as:
Mean · percentage of curvature change
Percentage Change From Baseline in Penile Curvature
percentage of curvature changeAA4500Placebo
Percentage Change From Baseline in Penile Curvature-37.6 ± 30.29-21.3 ± 29.89
Statistical analysis
  • AA4500 vs Placebo · ANOVA · p = 0.0005
PrimaryChange From Baseline in the Peyronie's Disease Bother Domain of the Peyronie's Disease Questionnaire (PDQ)

Peyronie's disease bother score range 0 (no issue or not at all bothered) to 4 (extremely bothered) on 4 questions; total score range 0 to 16. A decrease in the change from baseline total score in the Peyronie's disease bother domain of the PDQ is indicated by a negative number.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in the Peyronie's Disease Bother Domain of the Peyronie's Disease Questionnaire (PDQ)
units on a scaleAA4500Placebo
Change From Baseline in the Peyronie's Disease Bother Domain of the Peyronie's Disease Questionnaire (PDQ)-3.3 ± 3.83-2.0 ± 3.53
Statistical analysis
  • AA4500 vs Placebo · ANOVA · p = 0.0451
SecondaryA Responder Analysis Based on Subject Overall Global Assessment of Peyronie's Disease

A responder was defined as a subject who recorded his Peyronie's disease had either improved in a small but important way, moderately improved, or much improved in overall global assessment question.

Time frame:
Week 52
Reported as:
Number · Number of particpants
A Responder Analysis Based on Subject Overall Global Assessment of Peyronie's Disease
Number of particpantsAA4500Placebo
Responder Status-No6773
Responder Status-Yes13130
Responder Status-Missing11
Statistical analysis
  • AA4500 vs Placebo · Cochran-Mantel-Haenszel · p = <.0001
SecondaryChange From Baseline in the Severity of Peyronie's Disease Physical and Psychological Symptoms

Peyronie's disease symptoms (physical and psychological) severity score range 0 (none) to 4 (very severe) on 6 questions; total score range 0 to 24. A decrease in the change from baseline total score in the Peyronie's disease symptoms domain of the PDQ is indicated by a negative number.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in the Severity of Peyronie's Disease Physical and Psychological Symptoms
units on a scaleAA4500Placebo
Change From Baseline in the Severity of Peyronie's Disease Physical and Psychological Symptoms-3.2 ± 5.23-1.6 ± 4.50
Statistical analysis
  • AA4500 vs Placebo · ANOVA · p = 0.0268
SecondaryChange in the Overall Satisfaction Domain of the International Index of Erectile Function (IIEF)

Overall satisfaction domain of the IIEF score range 0 to 5 on 2 questions where higher scores indicate improved function or satisfaction; total score range 0 to 10.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change in the Overall Satisfaction Domain of the International Index of Erectile Function (IIEF)
units on a scaleAA4500Placebo
Change in the Overall Satisfaction Domain of the International Index of Erectile Function (IIEF)1.0 ± 2.550.5 ± 2.42
Statistical analysis
  • AA4500 vs Placebo · ANOVA · p = 0.0800
SecondaryChange From Baseline in Penile Plaque Consistency

Penile plaque consistency score range 1 (non-palpable) to 5 (hard). A decrease in the change from baseline score in penile plaque consistency is indicated by a negative number.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in Penile Plaque Consistency
units on a scaleAA4500Placebo
Change From Baseline in Penile Plaque Consistency-0.7 ± 0.97-0.6 ± 0.84
Statistical analysis
  • AA4500 vs Placebo · ANOVA · p = 0.3085
SecondaryChange From Baseline in Penile Length

A negative value represents a reduction in measurement from baseline.

Time frame:
Baseline and Week 52
Reported as:
Mean · centimeters
Change From Baseline in Penile Length
centimetersAA4500Placebo
Change From Baseline in Penile Length0.4 ± 1.290.1 ± 1.11
Statistical analysis
  • AA4500 vs Placebo · ANOVA · p = 0.6321
SecondaryChange From Baseline in the Penile Pain Domain of the PDQ in Subjects With Baseline Penile Pain Score ≥4

Penile pain scale range 0 (no pain) to 10 (extreme pain) on 3 questions; total score range 0 to 30. A decrease in the change from baseline total score in the penile pain domain of the PDQ is indicated by a negative number. Subjects were required to have a penile pain score of 4 or greater at baseline.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in the Penile Pain Domain of the PDQ in Subjects With Baseline Penile Pain Score ≥4
units on a scaleAA4500Placebo
Change From Baseline in the Penile Pain Domain of the PDQ in Subjects With Baseline Penile Pain Score ≥4-5.1 ± 5.16-4.0 ± 4.09
Statistical analysis
  • AA4500 vs Placebo · ANOVA · p = 0.7965
SecondaryComposite Responder Based on Change in Curvature Deformity and Change in Peyronie's Disease Bother Score

A responder was defined as a subject who satisfied the following 2 criteria at that visit: a) percent reduction from baseline in curvature deformity was ≥20% and b) reduction from baseline in PDQ Peyronie's disease bother score was ≥1, or had a change from reporting no sexual activity at screening to reporting sexual activity.

Time frame:
Week 52
Reported as:
Number · Number of participants
Composite Responder Based on Change in Curvature Deformity and Change in Peyronie's Disease Bother Score
Number of participantsAA4500Placebo
Responder Status No12997
Responder Status yes13233
Responder- Missing1610
Statistical analysis
  • AA4500 vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001

Adverse events

Collected over Throughout the study. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AA4500—27/277 (9.7%)248/277 (89.5%)
Placebo—7/140 (5%)55/140 (39.3%)
Most frequent serious events
Showing 10 of 40
Most frequent serious events
EventAA4500Placebo
Pulmonary embolismRespiratory, thoracic and mediastinal disorders3/2770/140
Road traffic accidentInjury, poisoning and procedural complications2/2770/140
Penile hematomaReproductive system and breast disorders2/2770/140
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/2771/140
SciaticaNervous system disorders1/2771/140
AppendicitisInfections and infestations0/2771/140
Hodgkin's diseaseNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2771/140
Carcinoma in situ penisNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2771/140
ArthritisMusculoskeletal and connective tissue disorders0/2771/140
DiverticulumGastrointestinal disorders0/2771/140
Most frequent other events
Showing 10 of 12
Most frequent other events
EventAA4500Placebo
Penile haematomaReproductive system and breast disorders171/27719/140
Penile painReproductive system and breast disorders119/27711/140
Penile swellingReproductive system and breast disorders114/2771/140
Injection site painGeneral disorders70/2775/140
Penile haemorrhageReproductive system and breast disorders60/27714/140
injection site haematomaGeneral disorders45/27714/140
Penile oedemaReproductive system and breast disorders45/2771/140
Injection site swellingGeneral disorders30/2770/140
ContusionInjury, poisoning and procedural complications28/2770/140
EcchymosisSkin and subcutaneous tissue disorders26/2770/140

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)AA4500PlaceboTotal
<=18 years000
Between 18 and 65 years226108334
>=65 years513283
Age, Continuous
Age, Continuous(years)AA4500PlaceboTotal
Mean57.9 ± 8.2258.2 ± 8.9458.0 ± 8.46
Sex: Female, Male
Sex: Female, Male(Participants)AA4500PlaceboTotal
Female000
Male277140417
Region of Enrollment
Region of Enrollment(participants)AA4500PlaceboTotal
United States223113336
Australia542781
08

Study locations

34 sites
  • Urology Centers of Alabama, PC
    Homewood, Alabama 35209, United States
  • HOPE Research Institute, LLC
    Phoenix, Arizona 85050, United States
  • Urology Associates Medical Group
    Burbank, California 91505, United States
  • California Professional Research
    Newport Beach, California 92660, United States
  • San Diego Sexual Medicine
    San Diego, California 92120, United States
  • Grove Hill Clinical Research, Grove Hill Medical Center
    New Britain, Connecticut 06052, United States
  • The Urology Center, PC
    New Haven, Connecticut 06511, United States
  • DCT-Celebration, LLC dba Discovery Clinical Trials
    Celebration, Florida 34747, United States
  • Palm Beach Urology Associates
    Wellington, Florida 33414, United States
  • Southeastern Medical Research Institute
    Columbus, Georgia 31904, United States
  • DuPage Medical Group
    Downers Grove, Illinois 60515, United States
  • Urology of Indiana LLC
    Avon, Indiana 46123, United States
  • Chesapeake Urology Research Associates
    Baltimore, Maryland 21204, United States
  • Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
  • Mens Health Boston
    Brookline, Massachusetts 02445, United States
  • Mayo Clinic at Rochester, Dept. of Urology
    Rochester, Minnesota 55905, United States
  • Center for Reproductive Medicine
    Hackensack, New Jersey 07601, United States
  • Division of Urology at Maimonides Medical Center
    Brooklyn, New York 11235, United States
  • Alliance Urology Specialists, PA
    Greensboro, North Carolina 27403, United States
  • Wake Urological Associates
    Raleigh, North Carolina 27607, United States
  • Tristate Urologic Services PSC Inc. dba TUG Research
    Cincinnati, Ohio 45212, United States
  • Urology Health Specialists,LLC
    Bryn Mawr, Pennsylvania 19010, United States
  • Urological Associates of Lancaster
    Lancaster, Pennsylvania 17604, United States
  • Alpha Clinical Research, LLC
    Clarksville, Tennessee 37043, United States
  • Urology Associates of North Texas
    Arlington, Texas 76017, United States
  • Baylor College of Medicine, Department of Urology
    Houston, Texas 77030, United States
  • Salt Lake Research, PLLC
    Salt Lake City, Utah 84107, United States
  • Urology of Virginia - Sentara Medical Group
    Norfolk, Virginia 23502, United States
  • Medical College of Wisconsin, Department of Urology
    Milwaukee, Wisconsin 53226, United States
  • Australian Centre for Sexual Health
    St. Leonards, New South Wales NSW 2065, Australia
  • Western Urology
    Westmead, New South Wales NSW 2145, Australia
  • AusTrials
    Kipparing, Queensland QLD 4019, Australia
  • Repatriation General Hospital
    Daws Park, South Australia SA 5041, Australia
  • Australian Urology Associates Pty Ltd
    Malvern, Victoria VIC 3144, Australia
09

References and documents

Publications

  • Hellstrom WJ, Feldman RA, Coyne KS, Kaufman GJ, Smith TM, Tursi JP, Rosen RC. Self-report and Clinical Response to Peyronie's Disease Treatment: Peyronie's Disease Questionnaire Results From 2 Large Double-Blind, Randomized, Placebo-Controlled Phase 3 Studies. Urology. 2015 Aug;86(2):291-8. doi: 10.1016/j.urology.2015.04.047. Epub 2015 Jul 18. PubMed 26199168 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2010, a primary completion of Apr 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2015, 3 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2010
First posted
Oct 15, 2010
Start
Sep 2010
Primary completionActual
Apr 2012
CompletionActual
Apr 2012
Results first posted
Apr 7, 2015
Last update
Oct 5, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 5, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01221597
Responsible party
Sponsor
First posted
Oct 15, 2010
Start date
Sep 2010
Primary completion
Apr 2012
Completion
Apr 2012
Results posted
Apr 7, 2015
Last update
Oct 5, 2017

Study contacts

Gregory J. Kaufman, MD
study director · Auxilium Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Microbial Collagenase

Start the discussion